Marinus Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Director Ezickson Elan reports the disposal of common stock and stock options in Marinus Pharmaceuticals following the merger agreement with Immedica Pharma AB.
Form 4: Marinus Pharmaceuticals Director Fischer Sells Shares and Options in Merger with Immedica Pharma AB
Director Seth H. Z. Fischer reports the sale of Marinus Pharmaceuticals shares and termination of stock options following the merger agreement with Immedica Pharma AB.
Joseph Hulihan, Chief Medical Officer of Marinus Pharmaceuticals, reports the disposal of common stock and termination of stock options following the merger agreement with Immedica Pharma AB.
Director Marvin Johnson reports the disposal of common stock and termination of stock options in Marinus Pharmaceuticals following the merger agreement with Immedica Pharma AB.
Martha Manning, SVP of Marinus Pharmaceuticals, reports the disposal of shares and stock options following the merger agreement with Immedica Pharma AB.
Director Timothy Mayleben reports the disposal of common stock and stock options due to the merger agreement with Immedica Pharma AB, where shares were acquired at $0.55 per share.
Following the merger agreement between Marinus Pharmaceuticals and Immedica Pharma AB, CFO Steven Pfanstiel reports the disposal of common stock and stock options.
Christina Shafer, Chief Commercial Officer of Marinus Pharmaceuticals, reports the disposition of common stock and stock options following the merger agreement with Immedica Pharma AB.
Form 4: Marinus Pharmaceuticals Chairman and CEO Reports Changes in Beneficial Ownership Following Merger
Scott Braunstein, Chairman and CEO of Marinus Pharmaceuticals, reports changes in beneficial ownership of common stock and derivative securities following the merger with Immedica Pharma AB.
Form 4: Marinus Pharmaceuticals Director Silverstein Reports Share Disposal Following Merger Agreement
Christine Berni Silverstein, a director at Marinus Pharmaceuticals, reported the disposal of common stock and stock options following the merger agreement with Immedica Pharma AB.
Director Elan Ezickson sold 1,600 shares of Marinus Pharmaceuticals common stock on January 21, 2025, to cover tax obligations related to vesting restricted stock units.
Director Marvin Johnson sold 1,610 shares of Marinus Pharmaceuticals common stock at $0.54 per share on January 21, 2025, to cover tax obligations related to vesting restricted stock units.
Form 4: Marinus Pharmaceuticals Director Timothy Mayleben Corrects Ownership Reporting in Form 4 Filing
Timothy Mayleben, a director at Marinus Pharmaceuticals, filed a Form 4 to correct previous reporting errors related to his holdings of common stock, including adjustments for clerical and administrative inaccuracies and transfers to family trusts.
CFO and COO of Marinus Pharmaceuticals, Steven Pfanstiel, sold 4,657 shares of common stock to cover tax obligations related to vesting restricted stock units.
Christina Shafer, Chief Commercial Officer of Marinus Pharmaceuticals, sold 3,820 shares of common stock on August 5, 2024, to cover tax obligations related to vesting restricted stock units.
Martha E. Manning, SVP, General Counsel & Corporate Secretary of Marinus Pharmaceuticals, sold 3,621 shares of common stock on August 5, 2024, to cover tax obligations related to vesting restricted stock units.
Form 4: Marinus Pharmaceuticals' Chief Medical Officer Hulihan Sells Shares to Cover Tax Obligations
Chief Medical Officer of Marinus Pharmaceuticals, Joseph Hulihan, sold 4,828 shares of common stock on August 5, 2024, to cover tax obligations related to vesting restricted stock units.
Marinus Pharmaceuticals CEO Scott Braunstein sold 12,145 shares of common stock on August 5, 2024, to cover tax obligations related to vesting restricted stock units.
Director Christine Silverstein reported the acquisition of restricted stock units and stock options in Marinus Pharmaceuticals, according to a Form 4 filing.
Director Sarah B. Noonberg acquired stock options and restricted stock units in Marinus Pharmaceuticals on June 18, 2024.
Director Timothy Mayleben reported the acquisition of restricted stock units and stock options in Marinus Pharmaceuticals, Inc.
Director Sara Nochur reports acquisition of restricted stock units and stock options in Marinus Pharmaceuticals.
Director Marvin Johnson acquired restricted stock units and stock options in Marinus Pharmaceuticals on June 18, 2024.
Director Seth H. Fischer acquired shares and options in Marinus Pharmaceuticals, according to a recent SEC Form 4 filing.
Director Elan Ezickson reported the acquisition of restricted stock units and stock options, as well as the disposal of common stock.
Director Charles Austin acquired 2,300 shares of common stock and options to purchase 10,450 shares of Marinus Pharmaceuticals stock on June 18, 2024.
Christina Shafer, Chief Commercial Officer of Marinus Pharmaceuticals, was granted stock options and restricted stock units on June 18, 2024.
Martha Manning, SVP, General Counsel & Corporate Secretary of Marinus Pharmaceuticals, reports the acquisition of restricted stock units and stock options.
Form 4: Marinus Pharmaceuticals' Chief Medical Officer Receives Stock Options and Restricted Stock Units
Chief Medical Officer of Marinus Pharmaceuticals, Joseph Hulihan, reports acquisition of stock options and restricted stock units.
CFO and COO of Marinus Pharmaceuticals, Steven Pfanstiel, reports the acquisition of restricted stock units and stock options.